The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer ...

Genetic testing specialist 23andMe has launched a strategic review that could result in a sale of the company, after months of speculation about its future. The company's board has formed a ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses. The company that made its name by providing saliva ...

Anne Wojcicki is at it again. After a failed attempt to buy back the DNA testing company she cofounded, the CEO has made another offer to gain control of 23andMe. But if the sale goes through ...

Morning. Today, we talk about the likely confirmation of FDA nominee Marty Makary, go in-depth on NIH nominee Jay Bhattacharya, and see how much 23andMe CEO Anne Wojcicki is willing to pay for her ...

When evaluating 23andMe's stock performance and future outlook, investors should consider short-term market trends and long-term growth potential. This analysis will dive into recent stock metrics ...

The genetic testing company 23andMe has agreed to pay $30 million to American plaintiffs to settle a lawsuit over a data breach last year that specifically targeted customers of Ashkenazi Jewish ...

23andMe ME-6.80%decrease; red down pointing triangle rejected its chief executive’s proposal to buy back the company at 41 cents a share as the struggling company explores strategic alternatives ...

23andMe (ME) stock nosedived over 33% yesterday after the board unanimously rejected CEO Anne Wojcicki’s takeover offer. The company has set up a Special Committee of the Board of Directors to ...